Diagnosis of cholangiocarcinoma in patients with PSC: A sight on cytology

Baskin-Bey, Edwina S.; Luna, Laura E. Moreno; Gores, Gregory J.

doi:10.1016/j.jhep.2006.07.006

Cited by 19 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, later studies have not confirmed these results [10]. ERC or PTC allows brushing of the strictures but brush cytology is hampered by low sensitivity [11,12] and negative biopsies and brushings do not exclude cholangiocarcinoma [13].…”

Section: Introductionmentioning

confidence: 98%

Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures

Lempinen

Isoniemi

Mäkisalo

et al. 2007

Journal of Hepatology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures

Lempinen

Isoniemi

Mäkisalo

et al. 2007

Journal of Hepatology

View full text Add to dashboard Cite

“…In many cases of suspected CCA after a transplant, pathology is unable to detect a malignancy. 19 Detecting specific biomarkers in peripheral blood samples may help clarify the diagnosis. 20 For patients with PSC, LT should be discussed as the more potent and definite solution than resection.…”

Section: Status Quomentioning

confidence: 99%

“…[27][28][29] If extended extrahepatic bile duct resection, including pancreatic head resection in combination with LT, leads to improved survival in extrahepatic CCA patients; however, partly because of increased perioperative mortality, most centers do not have improved results with this patient collective. [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] For patients with anatomically unresectable Klatskin tumors or considerable parenchymal damage, extended liver resection is not a choice. For these patients, LT is the only chance for a potential cure.…”

Section: Status Quomentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2015

Exp Clin Transplant

View full text Add to dashboard Cite

Liver transplant is not a standard therapy for cholangiocarcinoma; complete surgical resection of the tumor is currently the treatment of choice. Palliative options offer only short-term survival.After initial recurrence rates after liver transplant for cholangiocarcinoma in the 1990s were unacceptably high, cholangiocarcinoma has been regarded widely as a contraindication to liver transplant. Ubiquitous organ shortage further supports this conviction. Careful patient selection and a rigorous perioperative treatment by radiochemotherapy have produced some impressive survival data in specialized transplant centers in recent years. Although the graft shortage is aggravating in the Western world, the issue of liver transplant as a treatment for irresectable cholangiocarcinoma is being discussed.This review article provides an update and overview on the current status of liver transplant as a potential option for patients with irresectable cholangiocarcinoma.

show abstract

“…29,30 Diagnostic accuracy is increased when the pathologist is aware of the clinical features, CA-19-9 is >20 U/ml, and advanced cytology techniques like digitized image analysis (DIA) and FISH are used. 30,31 Non-diagnostic cytology or biopsy results should not rule out malignancy in the appropriate clinical and radiological setting.…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%